ASX:ALL} is under Algo Engine buy conditions.
ALL reported normalised 1H22 sales +23% to $2.74bn and EBITDA up +31% $970mn. The share price will remain well supported by the announced on market A$500 mn share buyback program.
You're not a member! Trial today
FY23 revenue growth of 7% and EBITDA 10%+, places the stock on 17x forward earnings and a 2.2% yield
